# A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06598007/  
OnCo record `nct06598007` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FOLFOX, FLOT, CAPOX in colorectal cancer and pancreatic ductal adenocarcinoma, run by Crossignal Therapeutics, Inc., now recruiting.

## Summary

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06598007 by Crossignal Therapeutics, Inc., with 78 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-06-20. Interventions recorded: CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin). Conditions listed: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06598007
- Phase: 1/2
- Setting: A Phase 1/2 First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients With Advanced Solid Tumors
- Sponsor: Crossignal Therapeutics, Inc.
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT06598007: https://clinicaltrials.gov/study/NCT06598007

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [CT3001](https://onco.cc/drugs/ct3001/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)

---
JSON: https://onco.cc/api/v1/entities/nct06598007.json